Has Jaymon Patel, MD received payments from drug or device companies?

Yes. Drug and device makers reported $42,100 in general payments to Jaymon Patel, MD across 238 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jaymon Patel, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jaymon Patel, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jaymon Patel, MD

Gastroenterology · Mattoon, ILNPI 1386084044

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $26,875 of the $42,100 with a category attached, or 63.8%. Phathom Pharmaceuticals, Inc. accounts for 89.2% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $19,752, more than ten times the $309 reported in 2019. Among gastroenterology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$42,100in general payments, 2019–2025

Across 238 payments — averaging $176.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Phathom Pharmaceuticals, Inc.$38K
AbbVie$2K
Johnson & Johnson$520
Takeda Pharmaceuticals U.S.A., Inc.$454
Janssen Scientific Affairs, LLC$372
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$332
plus $1K from 17 others

What the payments were for

Speaking & faculty fees$26,87564%
Travel & lodging$9,45622%
Food & beverage$5,61813%
Education$1510%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Phathom Pharmaceuticals, Inc.	38	$37,535
AbbVie	85	$1,861
Johnson & Johnson(2 entities)	31	$520
Takeda Pharmaceuticals U.S.A., Inc.	11	$454
Janssen Scientific Affairs, LLC	4	$372
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	20	$332
Gilead	11	$176
Bristol Myers Squibb	10	$151
Intercept Pharmaceuticals, Inc.	2	$123
Lilly USA, LLC	6	$101
Pfizer	4	$90
Redhill Biopharma Inc.	1	$76
Boehringer Ingelheim	1	$75
Merck	3	$51
Madrigal Pharmaceuticals	2	$46
Organon	1	$25
Daiichi Sankyo Inc.	1	$24
Nestle Healthcare Nutrition Inc.	2	$23
Ardelyx, Inc.	1	$15
Regeneron Healthcare Solutions, Inc.	1	$14
Medtronic	1	$13
Alfasigma USA, Inc.	1	$12
Micro-tech Endoscopy USA, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VOQUEZNA$37,076
Mavyret$125
Tremfya$124
Rinvoq$117
Entyvio$117
OCALIVA$109
STELARA$104

How this compares

$42,100 in reported general payments places this provider in the 90th percentile of 787 gastroenterology providers in Illinois.

See all gastroenterology providers in Illinois →

Medicare billing

Part B allowed, 2024

$96,445

Medicare patients

315

Services billed

774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg	133	$2,520
Sucralfate	43	$2,267
Omeprazole	110	$1,651
Pantoprazole Sodium	127	$1,577
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl	14	$255
Famotidine	15	$202
Gavilyte-NSodium Chloride/Nahco3/Kcl/Peg	14	$161

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Mattoon

David RubinChicago$1.5M
Stephen HanauerChicago$1.4M
Steven FlammChicago$1.3M
Amar NaikDes Plaines$1.2M
Darren BrennerChicago$1.1M
Jonathan RosenbergGurnee$1M
Daksesh PatelEvanston$745K
Russell CohenChicago$690K
Parambir DulaiChicago$668K
Christopher ChapmanChicago$645K

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →